ATE405254T1 - Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase - Google Patents

Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase

Info

Publication number
ATE405254T1
ATE405254T1 AT99946522T AT99946522T ATE405254T1 AT E405254 T1 ATE405254 T1 AT E405254T1 AT 99946522 T AT99946522 T AT 99946522T AT 99946522 T AT99946522 T AT 99946522T AT E405254 T1 ATE405254 T1 AT E405254T1
Authority
AT
Austria
Prior art keywords
tolterodine
antimuscarino
act
treatment
hyperactive bladder
Prior art date
Application number
AT99946522T
Other languages
English (en)
Inventor
Jacobsen Lene Orup
Rd Bo Kreilg
Ulla Hoeck
Helle Kristensen
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE405254(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of ATE405254T1 publication Critical patent/ATE405254T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99946522T 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase ATE405254T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
ATE405254T1 true ATE405254T1 (de) 2008-09-15

Family

ID=20412370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946522T ATE405254T1 (de) 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase

Country Status (13)

Country Link
US (2) US6517864B1 (de)
EP (1) EP1105111B1 (de)
JP (1) JP2002523446A (de)
AT (1) ATE405254T1 (de)
AU (1) AU758399B2 (de)
CA (1) CA2341063C (de)
DE (1) DE69939382D1 (de)
ES (2) ES2310942T3 (de)
NZ (1) NZ509928A (de)
SE (1) SE9802864D0 (de)
TW (1) TWI253349B (de)
WO (1) WO2000012070A1 (de)
ZA (1) ZA200002488B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0924983A4 (de) * 1996-07-19 1999-08-25 Gunnar Aberg S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
EP0957073A1 (de) * 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
EP1031346B1 (de) 1999-01-27 2002-05-02 Idea Ag Nichtinvasive Impfung durch die Haut
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
EP1455697A4 (de) * 2001-12-20 2009-08-05 Femmepharma Holding Co Inc Vaginale verabreichung von arzneimitteln
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
WO2004060322A2 (en) * 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040191345A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US20060188554A1 (en) * 2003-08-04 2006-08-24 Katashi Nakashima Transdermal absorption preparation
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US20110071204A1 (en) * 2005-02-03 2011-03-24 Kyorin Pharmaceutical Co., Ltd. Percutaneous absorption preparation
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
AU2012261753B2 (en) * 2006-04-13 2015-03-05 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
CA2650412C (en) * 2006-04-13 2016-09-27 Nupathe, Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
EP2019679B1 (de) 2006-05-23 2018-06-20 Theracos, Inc. Glucosetransporthemmer und anwendungsverfahren
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
WO2008083158A2 (en) * 2006-12-26 2008-07-10 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
RU2492175C2 (ru) 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
ES2654894T3 (es) 2007-08-23 2018-02-15 Theracos Sub, Llc Derivados de (2S,3R,4R,5S,6R)-2-(4-cloro-3-bencilfenil)-6-(hidroximetil)tetrahidro-2H-piran-3,4,5-triol para su uso en el tratamiento de diabetes
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
EP2307546A1 (de) * 2008-06-04 2011-04-13 Coda Therapeutics, Inc. Schmerzbehandlung mit gap-junction-modulationsverbindungen
US8155737B2 (en) * 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
MX2011001855A (es) 2008-08-22 2011-03-24 Theracos Inc Procesos para la preparacion de inhibidores de sglt2.
EP2379561B1 (de) 2008-11-25 2015-11-04 University Of Rochester Mlk-inhibitoren und anwendungsverfahren
US8697661B2 (en) 2009-06-24 2014-04-15 Christine Kritikou Use of spinosyns and spinosyn compositions against herpesviridae viral infections
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US8845612B2 (en) * 2009-08-10 2014-09-30 Nupathe Inc. Methods for iontophoretically treating nausea and migraine
US20110087153A1 (en) * 2009-10-13 2011-04-14 Angelov Angel S Transdermal Methods And Systems For The Delivery Of Rizatriptan
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
KR20110094858A (ko) 2010-02-18 2011-08-24 에스케이케미칼주식회사 피부 자극이 감소한 톨테로딘의 경피 투여용 조성물
KR101746204B1 (ko) 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
CN102858372A (zh) * 2010-04-28 2013-01-02 久光制药株式会社 皮肤刺激抑制剂和经皮吸收制剂
CN103153994B (zh) 2010-05-24 2016-02-10 罗切斯特大学 双环杂芳基激酶抑制剂及使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
JP5642790B2 (ja) 2010-08-03 2014-12-17 久光製薬株式会社 貼付剤及びその粘着力増強方法
US20160184340A1 (en) 2010-12-22 2016-06-30 Christine Kritikou The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
EP3502236B1 (de) 2011-02-18 2023-08-23 The Scripps Research Institute Gezielte differenzierung von oligodendrozyten-vorläuferzellen zu einem myelinierungszellenschicksal
WO2013099835A1 (ja) 2011-12-27 2013-07-04 帝國製薬株式会社 トルテロジン含有貼付剤
CA2868534A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
CN104768567B (zh) 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
WO2013187451A1 (ja) 2012-06-12 2013-12-19 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014051128A1 (ja) 2012-09-28 2014-04-03 株式会社 ケイ・エム トランスダーム 貼付剤
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
CN103142465B (zh) * 2013-03-19 2014-10-22 长春健欣生物医药科技开发有限公司 一种托特罗定成膜水凝胶制剂及其制备方法
WO2015143240A2 (en) 2014-03-19 2015-09-24 Curza Global, Llc Compositions and methods comprising 2-(acylamino)imidazoles
US9987361B1 (en) 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology
EP3601232B1 (de) 2017-03-31 2022-11-23 Curza Global LLC Zusammensetzungen und verfahren mit substituierten 2-aminoimidazolen
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
WO2022020670A1 (en) * 2020-07-23 2022-01-27 Kimberly-Clark Worldwide, Inc. Method for modulating the bladder microbiome to improve bladder health
MX2023004941A (es) 2020-11-08 2023-07-12 Seagen Inc Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
JP2024514816A (ja) 2021-04-09 2024-04-03 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体を用いるがんの治療方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
JP3786684B2 (ja) * 1992-05-13 2006-06-14 アルザ・コーポレーション オキシブチニンの経皮投与
EP0924983A4 (de) * 1996-07-19 1999-08-25 Gunnar Aberg S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
DK0877600T3 (da) * 1996-08-09 2004-02-02 Alcon Mfg Ltd Konserveringssystem til farmaceutiske præparater indeholdende cyclodextrine
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Also Published As

Publication number Publication date
DE69939382D1 (de) 2008-10-02
US7008637B2 (en) 2006-03-07
CA2341063A1 (en) 2000-03-09
NZ509928A (en) 2003-08-29
ES2353765T3 (es) 2011-03-04
WO2000012070A1 (en) 2000-03-09
EP1105111A1 (de) 2001-06-13
AU758399B2 (en) 2003-03-20
JP2002523446A (ja) 2002-07-30
EP1105111B1 (de) 2008-08-20
CA2341063C (en) 2008-02-12
US6517864B1 (en) 2003-02-11
ZA200002488B (en) 2001-05-16
ES2310942T3 (es) 2009-01-16
TWI253349B (en) 2006-04-21
AU5891999A (en) 2000-03-21
US20030124179A1 (en) 2003-07-03
SE9802864D0 (sv) 1998-08-27

Similar Documents

Publication Publication Date Title
ATE405254T1 (de) Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
IS2789B (is) Lyfjablöndur sem innihalda mónóamínoxídasa B hemla
IS2803B (is) Fentanýlsamsetning fyrir gjöf í nef
BRPI0408153A (pt) formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
SE9803760D0 (sv) Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
HUP0203197A2 (hu) Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
Toda et al. Human uterine arterial relaxation induced by nitroxidergic nerve stimulation
SE9804126D0 (sv) New pharmaceutical composition
CO5690571A2 (es) Combinacion sinergica que comprende roflumilas y (r,r)-formoterol
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0407569A (pt) uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
SE0301885D0 (sv) New use IV
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0303610A2 (hu) Jóindulatú prosztatatúltengéssel összefüggő húgyhólyag-irritációs tünetek kezelésére alkalmas készítmény
DE60121978D1 (de) 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
EP1011672A4 (de) Verbindungen mit analgetischem effekt und zusammenstellungen die diese enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties